Information:
Fel:
ID
34565
Beskrivning
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone; ODM derived from: https://clinicaltrials.gov/show/NCT01516424
Länk
https://clinicaltrials.gov/show/NCT01516424
Nyckelord
Versioner (1)
- 2019-01-19 2019-01-19 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
19 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Schizophrenia NCT01516424
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Similar models
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
subject met dsm-iv-tr criteria for a primary diagnosis of schizophrenia
boolean
ID.2
Item
patients are 18≤age≤65 years of age on the day when informed consent is obtained.
boolean
ID.3
Item
subject had a panss total score ≥70 and 120≥ at screening
boolean
ID.4
Item
subject had a score ≥4 on the panss at screening and baseline.
boolean
ID.5
Item
subjects are willing and able to comply with study protocol including treatment in hospital.
boolean
ID.6
Item
subjects or their legal guardians have signed the written informed consent form.
boolean
ID.7
Item
the subject was treatment with other investigate product within 30 days.
boolean
ID.8
Item
subject had a history of treatment with long-acting drug for anti schizophrenia within 56 days.
boolean
ID.9
Item
subject had a history of treatment with clozapine within 28 days.
boolean
ID.10
Item
subject with parkinson disease,etc
boolean